Solid Biosciences Inc. (SLDB) - 10-K Summary
Business Context and Reporting Period
Company: Solid Biosciences Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Solid Biosciences is a clinical-stage life sciences company developing gene therapy candidates for rare neuromuscular and cardiac diseases. The company's lead programs include SGT-003 for Duchenne muscular dystrophy (DMD), SGT-212 for Friedreich's ataxia (FA), and SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT). The company has no commercial product revenue and relies on equity financing to fund operations.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(174.3) | $(124.7) |
| Research & Development Expenses | $140.3 | $96.4 |
| General & Administrative Expenses | $38.9 | $33.3 |
| Cash, Cash Equivalents & Investments (Dec 31, 2025) | $187.9 | $148.9 |
| Accumulated Deficit (Dec 31, 2025) | $(957.8) | $(783.5) |
Note: The company reported no debt outstanding as of December 31, 2025.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by 40% to $174.3 million in 2025 from $124.7 million in 2024, driven primarily by higher R&D spending.
- R&D Expense Surge: R&D expenses rose 45.5% to $140.3 million. This was largely due to a $43.8 million increase in costs for the lead candidate SGT-003 (Duchenne) related to manufacturing and clinical trial expansion, and a $5.0 million increase for SGT-601.
- Derivative Liability Impact: The company recognized a $6.1 million loss due to the change in fair value of derivative liabilities associated with milestone payments to FA212 LLC, compared to $4.8 million in 2024.
- Capital Raise: In March 2026 (subsequent to year-end), the company completed a private placement raising approximately $226.4 million in net proceeds.
Guidance, Outlook, and Risks
Clinical Progress & Outlook:
- SGT-003 (Duchenne): Positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial was announced in March 2026. The Phase 3 IMPACT DUCHENNE trial began screening in October 2025, with first dosing anticipated in April 2026. The company plans to seek FDA guidance on an accelerated approval pathway in mid-2026.
- SGT-212 (Friedreich's Ataxia): The Phase 1b FALCON trial dosed its first participant in January 2026. Initial data is expected in the second half of 2026.
- SGT-501 (CPVT): The Phase 1b ARTEMIS trial began screening in January 2026, with first dosing expected in the second quarter of 2026.
Liquidity: Management believes cash, cash equivalents, and available-for-sale securities as of December 31, 2025 ($187.9 million), combined with the March 2026 private placement proceeds, will fund operations into the first half of 2028. Additional funding will be required thereafter.
Key Risks:
- Profitability: The company has incurred significant losses since inception and expects to continue doing so for the foreseeable future.
- Capital Requirements: Failure to secure additional funding could force delays or termination of product development.
- Clinical Development: Risks include failure to demonstrate safety/efficacy, enrollment delays, and potential clinical holds (the company previously experienced a clinical hold on SGT-001).
- Manufacturing: Reliance on third-party manufacturers for complex gene therapy production poses supply chain and quality control risks.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $187.9 million year-end cash balance plus the $226.4 million March 2026 raise to cover the projected burn rate through mid-2028.
- SGT-003 Safety Profile: Review the details of the Grade 3 immune-mediated myositis adverse event reported in the INSPIRE DUCHENNE trial and the Data Safety Monitoring Board's recommendation to continue dosing.
- Phase 3 Trial Design: Confirm the alignment with the FDA on the IMPACT DUCHENNE trial design, specifically the primary endpoint (Time to Rise velocity) and patient population (ambulant 7 to <12 years).
- Derivative Liabilities: Monitor the fair value of derivative liabilities related to FA212 milestone payments, which fluctuated significantly ($6.1 million loss in 2025) and impact net loss.
- Manufacturing Scalability: Assess the company's progress in scaling transient transfection manufacturing processes to meet commercial demand, given reliance on third-party CDMOs.